145 related articles for article (PubMed ID: 29425684)
21. Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs.
Ito Y; Kondo J; Masuda M; Matsuzaki S; Onuma K; Kanda M; Watanabe Y; Sakaguchi H; Yoshino K; Ueda Y; Kamiura S; Kimura T; Inoue M
Hum Cell; 2023 Mar; 36(2):752-761. PubMed ID: 36474106
[TBL] [Abstract][Full Text] [Related]
22. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
Gallion H; Christopherson WA; Coleman RL; DeMars L; Herzog T; Hosford S; Schellhas H; Wells A; Sevin BU
Int J Gynecol Cancer; 2006; 16(1):194-201. PubMed ID: 16445633
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
[TBL] [Abstract][Full Text] [Related]
24. Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
Lum E; Vigliotti M; Banerjee N; Cutter N; Wrzeszczynski KO; Khan S; Kamalakaran S; Levine DA; Dimitrova N; Lucito R
Gynecol Oncol; 2013 Aug; 130(2):369-76. PubMed ID: 23684582
[TBL] [Abstract][Full Text] [Related]
25. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
26. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
27. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
28. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
[TBL] [Abstract][Full Text] [Related]
30. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
31. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients.
Agiostratidou G; Sgouros I; Galani E; Voulgari A; Chondrogianni N; Samantas E; Dimopoulos MA; Skarlos D; Gonos ES
Anticancer Res; 2001; 21(1A):455-9. PubMed ID: 11299779
[TBL] [Abstract][Full Text] [Related]
32. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
33. Quinacrine promotes autophagic cell death and chemosensitivity in ovarian cancer and attenuates tumor growth.
Khurana A; Roy D; Kalogera E; Mondal S; Wen X; He X; Dowdy S; Shridhar V
Oncotarget; 2015 Nov; 6(34):36354-69. PubMed ID: 26497553
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
35. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Lee YY; Jeon HK; Hong JE; Cho YJ; Ryu JY; Choi JJ; Lee SH; Yoon G; Kim WY; Do IG; Kim MK; Kim TJ; Choi CH; Lee JW; Bae DS; Kim BG
Oncotarget; 2015 Oct; 6(33):35040-50. PubMed ID: 26418900
[TBL] [Abstract][Full Text] [Related]
36. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
37. Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Lheureux S; N'Diaye M; Blanc-Fournier C; Dugué AE; Clarisse B; Dutoit S; Giffard F; Abeilard E; Briand M; Labiche A; Grellard JM; Crouet H; Martin S; Joly F; Poulain L
Int J Cancer; 2015 Mar; 136(5):E340-50. PubMed ID: 25066666
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo.
Zhang X; Wang X; Song X; Liu C; Shi Y; Wang Y; Afonja O; Ma C; Chen YH; Zhang L
Cancer Sci; 2010 Oct; 101(10):2163-70. PubMed ID: 20735432
[TBL] [Abstract][Full Text] [Related]
39. Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells.
Momeny M; Yousefi H; Eyvani H; Moghaddaskho F; Salehi A; Esmaeili F; Alishahi Z; Barghi F; Vaezijoze S; Shamsaiegahkani S; Zarrinrad G; Sankanian G; Sabourinejad Z; Hamzehlou S; Bashash D; Aboutorabi ES; Ghaffari P; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Int J Biochem Cell Biol; 2018 Jun; 99():1-9. PubMed ID: 29567488
[TBL] [Abstract][Full Text] [Related]
40. Prospective Clinical Correlation of the Histoculture Drug Response Assay for Ovarian Cancer.
Hoffman RM; Jung PS; Kim MB; Nam JH
Methods Mol Biol; 2018; 1760():73-81. PubMed ID: 29572795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
